Evidence map›Paper›PMID 36445360›Full record

ArticleImmunoHorizons2022

B Cell Activation Results in IKK-Dependent, but Not c-Rel- or RelA-Dependent, Decreases in Transcription of the B Cell Tolerance-Inducing Gene Ets1.

Alyssa Kearly, Kristina Ottens, Michael C Battaglia, Anne B Satterthwaite, Lee Ann Garrett-Sinha

Open access · goldAbstract read
In one paragraph

Article in ImmunoHorizons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alyssa KearlyDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY; and.
Kristina OttensDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Michael C BattagliaDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY; and.
Anne B SatterthwaiteDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Lee Ann Garrett-SinhaDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY; and.ORCID 0000-0001-7806-4352
University at Buffalo, State University of New York · USThe University of Texas Southwestern Medical Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Regulation and Consequences of Ets1 Downregulation in B CellsR01AI122720 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GARRETT-SINHA, LEE ANN, SATTERTHWAITE, ANNE B · 2016 to 2020
$2.6M
NCI NIH HHS P30 CA016056NIAID NIH HHS R01 AI122720
6 · The paper itself

Abstract

Ets1 is a key transcription factor in B cells that is required to prevent premature differentiation into Ab-secreting cells. Previously, we showed that BCR and TLR signaling downregulate Ets1 levels and that the kinases PI3K, Btk, IKK, and JNK are required for this process. PI3K is important in activating Btk by generating the membrane lipid phosphatidylinositol (3,4,5)-trisphosphate, to which Btk binds via its PH domain. Btk in turn is important in activating the IKK kinase pathway, which it does by activating phospholipase Cγ2→protein kinase Cβ signaling. In this study, we have further investigated the pathways regulating Ets1 in mouse B cells. Although IKK is well known for its role in activating the canonical NF-κB pathway, IKK-mediated downregulation of Ets1 does not require either RelA or c-Rel. We also examined the potential roles of two other IKK targets that are not part of the NF-κB signaling pathway, Foxo3a and mTORC2, in regulating Ets1. We find that loss of Foxo3a or inhibition of mTORC2 does not block BCR-induced Ets1 downregulation. Therefore, these two pathways are not key IKK targets, implicating other as yet undefined IKK targets to play a role in this process.

Indexed as

B-LymphocytesLymphocyte ActivationNF-kappa BProto-Oncogene Protein c-ets-1AnimalsI-kappa B KinaseMechanistic Target of Rapamycin Complex 2MicePhosphatidylinositol 3-KinasesEts1 protein, mouseI-kappa B KinaseMechanistic Target of Rapamycin Complex 2NF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Protein c-ets-1

Identifiers

PMID36445360
PMCPMC10069408
OpenAlexW4310643038

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.